AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18951459
Drug: Yale-Brown-Cornell Eating
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) pre- and post-treatment
Trial: 15678733
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion 15 microg kg(‐1) h(‐1)
Trial: 15678733
Drug: Alfentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil infusion 60 microg kg(‐1) h(‐1)
Trial: 12080408
Drug: Multi-micronutrient supplementation
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-micronutrient supplementation (daily tablet containing 1000 microg vitamin A)
Trial: 12080408
Drug: Multi-helminth chemotherapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-helminth chemotherapy (single treatment with albendazole 600 mg and praziquantel 40 mg/kg)
Trial: 26581683
Drug: Decaffeinated green
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated green tea extract (GTE) 1315 mg total catechins/d
Trial: 26581683
Drug: COMT high-activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMT high-activity (G/G) genotype
Trial: 22497967
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G-GR) 3000mg once daily (G-GR-QD)
Trial: 22497967
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G-GR) divided dose (G-GR-DD, 1200mg AM/1800mg PM)
Trial: 18539989
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 or 2.5 mg
Trial: 12917299
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin therapy (target INR of 1.5 to 1.9)
Trial: 12917299
Drug: Conventional-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-intensity warfarin therapy (target INR of 2.0 to 3.0)
Trial: 10622270
Drug: Iloprost treatment
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost treatment (0.5-2 ng/Kg/min)
Trial: 8556228
Drug: UFT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT therapy alone
Trial: 8556228
Drug: UFT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT therapy in combination with Bestatin
Trial: 6372066
Drug: Cimetidine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 1 g/day
Trial: 7034155
Drug: Antacid/anticholinergic (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid/anticholinergic (10 ml of antacid suspension and 0.6 mg L-hyoscyamine twice a day)
Trial: 7034155
Drug: Antacid/anticholinergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid/anticholinergic
Trial: 19261173
Drug: Intradermal influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal influenza vaccination
Trial: 20372083
Drug: Intradermal microinjection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal microinjection system
Trial: 20372083
Drug: Conventional intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intramuscular syringe
Trial: 18620598
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care and Procalcitonin guided diagnostics and treatment of infection
Trial: 16093865
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 60 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Trial: 16093865
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 36 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Trial: 9104690
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy in NC subjects
Trial: 1343921
Drug: Oxamniquine, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine, single dosage of 15 mg/kg for adults and 20 mg/kg for children divided in two doses
Trial: 1343921
Drug: Praziquantel, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel, single dose of 60 mg/kg
Trial: 1343921
Drug: Praziquantel, sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel, sequential doses of 60 mg/kg during 3 days or 30 mg/kg for 6 days
Trial: 1343921
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Oxamniquine and Praziquantel)
Trial: 3547254
Drug: Fluoromethalone 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoromethalone 0.1% suspension (FML)
Trial: 3547254
Drug: Higher penetration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher penetration steroids
Trial: 9379354
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg)
Trial: 18377975
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading dose, 10 mg daily maintenance)
Trial: 18377975
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, 75 mg daily maintenance)
Trial: 16775579
Drug: High soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High soy diet (two daily soy servings)
Trial: 17429240
Drug: Combination phototherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination phototherapy (n=15)
Trial: 31004470
Drug: Clazosentan (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (15 mg/hour for 3 hours) after rifampin (600 mg/100 mL in 30 minutes)
Trial: 31004470
Drug: Clazosentan (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (15 mg/hour for 3 hours) after placebo
Trial: 19816871
Drug: High bolus
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bolus dose tirofiban (25 microg/kg)
Trial: 19816871
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline bolus and infusion)
Trial: 19816871
Drug: High bolus
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bolus dose tirofiban (25 microg/kg) in patients with diabetes mellitus
Trial: 15133532
Drug: RPR749 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPR749 (200 mg)
Trial: 2680677
Drug: 12 mg/day
RxNorm normalized name: EMSAM 12 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/day piretanide
Trial: 2680677
Drug: 6 mg/day
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/day piretanide
Trial: 2680677
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day bendroflumethiazide
Trial: 1127136
Drug: naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (500 mg/day)
Trial: 24947791
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin peglispro (BIL) at doses ranging from 5.1 to 74.1 mU/min
Trial: 24947791
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at doses of 20 or 30 mU/m(2)/min
Trial: 19321988
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention group A (oral health instructions + extra reminders)
Trial: 19321988
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention group B (oral health instructions)
Trial: 20534421
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no erythropoietin treatment)
Trial: 9631134
Drug: Hydroxyurea (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (500 mg twice daily)
Trial: 2845043
Drug: DMSA 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA 350 mg/m2/day
Trial: 2845043
Drug: DMSA 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA 700 mg/m2/day
Trial: 2845043
Drug: DMSA 1050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA 1050 mg/m2/day
Trial: 2845043
Drug: CaNa2EDTA 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaNa2EDTA 1000 mg/m2/day
Trial: 31415213
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of vitamin D3 (0.3 ml, 100,000 IU (2.5 mg/ml))
Trial: 31415213
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of 2% zinc sulfate
Trial: 31823141
Drug: MTX-hold group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX-hold group (4-week discontinuation)
Trial: 21433074
Drug: d‐chlorpheniramine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐chlorpheniramine 2 mg
Trial: 19767812
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (5 mg/kg fat-free mass; approximately 208-270 mg)
Trial: 17530941
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (3.5 mg.kg(‐1) once weekly for 6 weeks)
Trial: 17530941
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline injections once weekly for 6 weeks)
Trial: 2258378
Drug: Sertraline (145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (145 mg daily)
Trial: 2258378
Drug: Amitriptyline (104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (104 mg daily)
Trial: 6795614
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg cefuroxime i.m. with premedication and then 8 hourly for 3 days (group A)
Trial: 6795614
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g cefuroxime i.v. at the time of induction of anaesthesia (group B)
Trial: 6806060
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group C)
Trial: 27986838
Drug: Cornstarch-based gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornstarch-based gel
Trial: 29328522
Drug: Commercial gel
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial gel
Trial: 23910063
Drug: Risperidone 2
RxNorm normalized name: risperidone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 2 mg orally before ERCP
Trial: 15603203
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of pure histamine (equaling 124 mg histamine dihydrochloride, dissolved in peppermint tea)
Trial: 22948897
Drug: Selegiline 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 10 mg/day
Trial: 27030562
Drug: Robotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic therapy using the Multi Joint System (MJS) device for 40 min, 5 days/week for 3 weeks, in addition to standard therapeutic physical exercises, massage, laser and pulsed current therapy.
Trial: 27030562
Drug: Standard therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapeutic physical exercises, massage, laser and pulsed current therapy (control group).
Trial: 25996101
Drug: Concurrent neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent neoadjuvant chemoradiotherapy (XELOX regimen)
Trial: 23213070
Drug: Allopurinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100 mg or 300 mg)
Trial: 21788967
Drug: Doxazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (4 mg) plus tolterodine SR (4 mg)
Trial: 21788967
Drug: Doxazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (4 mg) plus placebo
Trial: 19880460
Drug: STAR*D intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAR*D intervention (medication switching and augmentation)
Trial: 16391588
Drug: alpha‐tocopherol 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐tocopherol 200 mg and ascorbic acid 100 mg twice daily
Trial: 15349657
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug membrane
Trial: 9279492
Drug: Cocaine Stimuli
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine Stimuli Condition (0.4 mg/kg delivery of cocaine)
Trial: 9279492
Drug: Neutral Stimuli
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral Stimuli Condition (placebo, 5 mg)
Trial: 8333814
Drug: Chlorthalidone, 25
RxNorm normalized name: Chlorthalidone, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone, 25 mg/d
Trial: 8333814
Drug: Atenolol, 50
RxNorm normalized name: Atenolol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 50 mg/d
Trial: 2906255
Drug: Etintidine (E)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etintidine (E) HCl in capsules, ascending doses at 72‐h intervals
Trial: 28790056
Drug: Aqueous chlorhexidine
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous chlorhexidine (0.5% chlorhexidine aqueous solution)
Trial: 23743161
Drug: Yiqi Huaju
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Huaju Qingli formula treatment in combination with Western medicine
Trial: 23743161
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with Western medicine
Trial: 19859699
Drug: Glucose tablets
RxNorm normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose tablets
Trial: 1855729
Drug: Heparin-surface-modified PMMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-surface-modified PMMA IOL
Trial: 7042110
Drug: Methylprednisolone (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (2.0 g i.v. on admission and 2.0 g i.v. 3 hours later)
Trial: 31755803
Drug: Thyroxine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine treatment (Group A)
Trial: 31060544
Drug: Gastrectomy, CRS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrectomy, CRS and HIPEC after 3-4 cycles of systemic chemotherapy
Trial: 31060544
Drug: Palliative systemic
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative systemic chemotherapy only
Trial: 28643618
Drug: Heat-stabilised rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stabilised rice bran (30 g/d)
Trial: 26056862
Drug: Oriental medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oriental medicine music therapy (OMMT)
Trial: 18539337
Drug: Continuation phase
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation phase cognitive therapy (C‐CT) for 8 months
Trial: 15510599
Drug: UDCA (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (500 mg b.i.d)
Trial: 9562365
Drug: CrH2O (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CrH2O (4 x 5 g of CrH2O and 1 g glucose/day)
Trial: 8504634
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 x 6 g of glucose/day)
Trial: 23014081
Drug: Band and
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Band and loop (B&L) space maintainers
Trial: 25788173
Drug: Crown and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crown and loop (C&L) space maintainers
Trial: 18652323
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with inductance coupling treatment
Trial: 16827023
Drug: Onlay with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onlay with buccal and palatal cuspal coverage
Trial: 30146141
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) with homework completion after Sessions 2 and 3
Trial: 30146141
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) with homework completion after Sessions 8 and 9
Trial: 30146141
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) in the second half of treatment
Trial: 22761409
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of voriconazole
Trial: 22761409
Drug: Non-therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-therapeutic drug monitoring (non-TDM) of voriconazole
Trial: 18703472
Drug: Tibolone (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (1.25 mg once daily)
Trial: 2234856
Drug: Heparin surface-modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin surface-modified (HSM) lenses
Trial: 197800
Drug: Dexamethasone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (single oral dose)
Trial: 197800
Drug: Desoxycorticosterone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoxycorticosterone (single oral dose)
Trial: 197800
Drug: ACTH (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH (two i.v. injections of 60 IU each, at a 6-hour interval)
Trial: 26247327
Drug: Therapist-aided exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-aided exposure treatment for 3 months
Trial: 14535875
Drug: RBCAT (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBCAT (ranitidine bismuth citrate 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d.)
Trial: 14535875
Drug: PAL (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAL (pantoprazole 40 mg b.d. plus amoxicillin 1 g b.d. and levofloxacin 500 mg/day)
Trial: 14535875
Drug: PBTM (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBTM (pantoprazole 40 mg b.d., bismuth citrate 240 mg b.d., tetracycline 500 mg q.d.s. and metronidazole 500 mg b.d.)
Trial: 3294020
Drug: bepridil 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bepridil 900 mg followed by 300 mg daily for 11 days
Trial: 1603890
Drug: Triazolam 0.25
RxNorm normalized name: triazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.25 mg (active drug)
Trial: 373778
Drug: Secretolytic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secretolytic drugs
Trial: 28350328
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (50,000 IU of oral VitD3 once weekly for 8 weeks)
Trial: 19441980
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.7 mg/kg plus fluconazole 800 mg
Trial: 19441980
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.7 mg/kg plus fluconazole 400 mg
Trial: 19441980
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.7 mg/kg (standard therapy)
Trial: 9827927
Drug: Karnofsky index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karnofsky index > 60 and albuminaemia > or = 34 g/l
Trial: 9827927
Drug: Karnofsky index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karnofsky index < or = 60 and albuminaemia < 34 g/l
Trial: 8015506
Drug: Klimaxil (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klimaxil (17 beta‐estradiol 2 mg and medroxy‐progesterone acetate 5 mg)
Trial: 8015506
Drug: Divina (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divina (17 beta‐estradiol valerate 2 mg and medroxyprogesterone acetate 10 mg)
Trial: 8015506
Drug: Trisequence (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trisequence (17 beta‐estradiol 2 mg in the first phase) and Provera (medroxyprogesterone acetate 5 mg)